Avacopan for the Treatment of ANCA-Associated Vasculitis

Keyphrases

• Antineutrophil Cytoplasmic Antibody-associated Vasculitis 100%
• Avacopan 100%
• Prednisone 66%
• Remission 44%
• Non-inferiority 33%
• Sustained Remission 33%
• Rituximab 22%
• Birmingham Vasculitis Activity Score 22%
• Cyclophosphamide 22%
• Second Primary 22%
• 95% Confidence Interval 22%
• Disease Activity 11%
• Randomized Controlled Trial 11%
• Clinical Effect 11%
• Twice Daily 11%
• High-score 11%
• Serious Adverse Events 11%
• Vasculitis 11%
• Safety Impact 11%
• Glucocorticoid Use 11%
• C5a Receptor 11%
• Oral Prednisone 11%
• Receptor Inhibitors 11%

Pharmacology, Toxicology and Pharmaceutical Science

• ANCA Associated Vasculitis 100%
• Avacopan 100%
• Remission 77%
• Prednisone 77%
• Vasculitis 33%
• Rituximab 22%
• Cyclophosphamide 22%
• Disease Activity 11%
• Adverse Event 11%
• Randomized Controlled Trial 11%
• Glucocorticoid 11%
• Azathioprine 11%
• Complement Component C5a Receptor 11%

Medicine and Dentistry

• ANCA Associated Vasculitis 100%
• Avacopan 100%
• Prednisone 77%
• Vasculitis 33%
• Rituximab 22%
• Cyclophosphamide 22%
• Oral 22%
• Disease Activity 11%
• Adverse Event 11%
• Randomized Controlled Trial 11%
• Glucocorticoid 11%
• Azathioprine 11%
• Complement Component C5a Receptor 11%